- Eczemus (Tacrolimus) Ointment 0.03% is indicated for short-term and intermittent long-term therapy in the treatment of moderate to severe atopic dermatitis (eczema) in children.
- Eczemus (Tacrolimus) Ointment 0.1% is indicated for short-term and intermittent long-term therapy in the treatment of moderate to severe atopic dermatitis (eczema) in adults.
Eczemus®Ointment (Tacrolimus)
Tacrolimus is first FDA approved steroid free topical preparation for management of Eczema.
Eczemus (Tacrolimus) is a macrolide immunosuppressant produced by streptomyces tsukubaensis. Eczemus (Tacrolimus) inhibits T-lymphocyte activation by first binding to an intracellular protein,FKBP-12. Eczemus (Tacrolimus) has also been shown to inhibit the release of inflammatory mediators from skin mast cells, basophils and eosinophils. Eczemus (Tacrolimus) ointment does not affect collagen synthesis in humans.
Eczemus ointment 0.03% is supplied in the tube of 10g
Eczemus ointment 0.1% is supplied in the tube of 10g
